Frankfurt - Delayed Quote USD

PharmaEssentia Corporation (8Z1.F)

Compare

0.0000

-0.0100

(-100.00%)

As of September 19 at 8:17:04 AM GMT+2. Market Open.

PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage

BURLINGTON, Mass., March 04, 2025--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the latest National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2025, January 21, 2025) now highlight the substitution of ropeginterferon alfa-2b-njft (BESREMi®) for treating p

Business Wire last month

6446.TW
CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia

BURLINGTON, Mass., January 07, 2025--Please replace the release dated January 6, 2025, with the following corrected version due to multiple revisions.

Business Wire 3 months ago

6446.TW
PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challenges

BURLINGTON, Mass., January 02, 2025--In light of the reported global shortage of Pegasys® (peginterferon alfa-2a), PharmaEssentia (TWSE: 6446), a global biopharmaceutical company, reaffirms its enduring commitment to creating robust and reliable access to critical interferon therapies. Amidst growing global concerns about drug shortages of other therapies, PharmaEssentia’s established cGMP manufacturing network and patient-focused approach enable it to help meet the needs of healthcare providers

Business Wire 3 months ago

6446.TW
PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025

BURLINGTON, Mass., December 19, 2024--PharmaEssentia Corporation (TWSE: 6446), a global commercial biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025 at 1:45 pm. PST.

Business Wire 3 months ago

6446.TW
PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer

BURLINGTON, Mass., December 05, 2024--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Joseph R. Horvat as Global Chief Commercial Officer.

Business Wire 4 months ago

6446.TW
PharmaEssentia Announces Nine Data Presentations at ASH Annual Meeting

BURLINGTON, Mass., November 25, 2024--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced a slate of nine new abstracts exploring the use of ropeginterferon alfa-2b-njft, known in market as BESREMi®, will be presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.

Business Wire 4 months ago

6446.TW
PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada

BURLINGTON, Mass., September 04, 2024--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that it has entered into an exclusive licensing agreement with FORUS Therapeutics Inc ("FORUS") for the registration and distribution of BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera (PV), in Canada.

Business Wire 7 months ago

6446.TW

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PharmaEssentia Corporation (8Z1.F)

PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage

CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia

PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challenges

PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025

PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer

PharmaEssentia Announces Nine Data Presentations at ASH Annual Meeting

PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada